Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference

Rhea-AI Summary

Sol-Gel Technologies (Nasdaq: SLGL) announced its participation in two virtual conferences: the LifeSci Partners 11th Annual Corporate Access Event on January 5, 2022, featuring 1-on-1 meetings, and the H.C. Wainwright BioConnect 2022 Healthcare Conference, with a corporate presentation webcast available from January 10-13, 2022. The company focuses on developing topical drug products for skin diseases, leveraging its microencapsulation technology. The FDA is set to conduct a pre-approval inspection for its product EPSOLAY in February 2022, aiming for commercialization with Galderma.

NESS ZIONA, Israel, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in the LifeSci Partners 11^th Annual Corporate Access Event and the H.C. Wainwright BioConnect Conference, both of which will be held virtually.

Event details are as follows:

LifeSci Partners 11th Annual Corporate Access Event
Format	1-on-1 meetings
Date:	January 5, 2022
Registration	Link
H.C. Wainwright BioConnect 2022 Healthcare Conference
Format	Webcast of corporate presentation
Date:	Webcast on demand starting at 7:00 am ET January 10 through January 13, 2022
Registration	Link

About Sol-Gel Technologies 

Sol-Gel is a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol‑Gel leverages its proprietary microencapsulation technology platform for TWYNEO, which is FDA approved for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date that was set for April 26, 2021.  Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a pre‑approval inspection of the production site of EPSOLAY as a result of COVID‑19 travel restrictions. On December 21, 2021, Sol-Gel announced that FDA has updated Sol-Gel the pre-approval inspection for EPSOLAY will occur the week of February 14, 2022. Both product candidates are exclusively licensed for U.S. commercialization with Galderma. The Company’s pipeline also includes early-stage topical drug candidates SGT-210 (erlotinib gel) under investigation for the treatment of palmoplantar keratoderma, SGT-310 (tapinarof cream, 1%) and SGT-510 (roflumilast) under investigation for the treatment of plaque psoriasis and other dermatologic indications. For additional information, please visit www.sol-gel.com.

Contact:

Irina Koffler
Investor relations, LifeSci Advisors
ikoffler@lifesciadvisors.com
+1 917 734 7387

Sol-Gel Technologies
Gilad Mamlok
Chief Financial Officer
gilad.mamlok@sol-gel.com

FAQ

What are the upcoming events for Sol-Gel Technologies (SLGL) in January 2022?

Sol-Gel Technologies will participate in the LifeSci Partners 11th Annual Corporate Access Event on January 5, 2022, and the H.C. Wainwright BioConnect Conference from January 10-13, 2022.

What will Sol-Gel Technologies (SLGL) present at the H.C. Wainwright BioConnect Conference?

Sol-Gel Technologies will host a corporate presentation webcast at the H.C. Wainwright BioConnect Conference, available on demand from January 10-13, 2022.

What is the status of EPSOLAY from Sol-Gel Technologies (SLGL)?

The FDA plans to conduct a pre-approval inspection for EPSOLAY the week of February 14, 2022, after delays due to COVID-19.

How does Sol-Gel Technologies (SLGL) plan to commercialize its products?

Sol-Gel Technologies exclusively licenses its products, including TWYNEO and EPSOLAY, for U.S. commercialization with Galderma.

Where can I register for the LifeSci Partners event featuring Sol-Gel Technologies (SLGL)?

Registration for the LifeSci Partners 11th Annual Corporate Access Event can be completed through the provided link in the press release.